All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 24 points (-0.1%) at 18,483 as of Friday, July 15, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,378 issues advancing vs. 1,527 declining with 156 unchanged.

The Drugs industry currently sits up 0.5% versus the S&P 500, which is down 0.3%. Top gainers within the industry include

Vertex Pharmaceuticals

(

VRTX

), up 2.4%,

Incyte

(

INCY

), up 2.2%,

Regeneron Pharmaceuticals

(

REGN

), up 1.9% and

Celgene

(

CELG

), up 1.6%. On the negative front, top decliners within the industry include

Teva Pharmaceutical Industries

(

TEVA

), down 1.7%,

Shire

(

SHPG

), down 1.0%,

Sanofi

(

SNY

), down 0.8%,

Eli Lilly and

(

LLY

), down 0.7% and

Pfizer

(

PFE

), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Biomarin Pharmaceutical

(

BMRN

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biomarin Pharmaceutical is up $4.84 (5.4%) to $93.87 on heavy volume. Thus far, 1.7 million shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $89.19-$94.75 after having opened the day at $89.70 as compared to the previous trading day's close of $89.03.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $14.1 billion and is part of the health care sector. Shares are down 15.0% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Biomarin Pharmaceutical

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Biomarin Pharmaceutical Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Biogen

(

BIIB

) is up $6.01 (2.4%) to $258.88 on average volume. Thus far, 1.2 million shares of Biogen exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $253.81-$259.98 after having opened the day at $254.11 as compared to the previous trading day's close of $252.87.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen has a market cap of $55.0 billion and is part of the health care sector. Shares are down 17.5% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Biogen a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Biogen

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Biogen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is up $1.53 (1.8%) to $87.07 on average volume. Thus far, 6.9 million shares of Gilead exchanged hands as compared to its average daily volume of 9.5 million shares. The stock has ranged in price between $85.54-$87.96 after having opened the day at $85.67 as compared to the previous trading day's close of $85.54.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $114.2 billion and is part of the health care sector. Shares are down 15.5% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts who rate Gilead a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).